BofA Starts Coverage of Inhibikase Therapeutics with Buy Rating
BofA gives Inhibikase Therapeutics (IKT) a Buy rating with $6 target, citing strong data, regulatory support, and promising leukemia therapy for PAH.
/ 2 items
BofA gives Inhibikase Therapeutics (IKT) a Buy rating with $6 target, citing strong data, regulatory support, and promising leukemia therapy for PAH.
H.C. Wainwright begins coverage of Inhibikase Therapeutics with a Buy rating and $8 target, citing strong prospects for its Phase 3 PAH drug IKT-001.